ArticleThe New England journal of medicine2015
Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
Article in The New England journal of medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03480568 (A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen), which is not on this map. Cited by 60 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen: The Alidial Study
Who cites it
60 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons.European heart journal. Quality of care & clinical outcomes · 2018Pooled it
- Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.Circulation · 2018Trial
- Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study.Lipids in health and disease · 2017Trial
- Impact of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor on Immune-Inflammatory Responses in the Acute Phase of Ischemic Stroke.Journal of inflammation research · 2026Article
- Observational
- PCSK9 Inhibitors: Focus on Evolocumab and Its Impact on Atherosclerosis Progression.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Cancer and Cardiovascular Disease: The Conjoined Twins.Cancers · 2024Review
- PCSK9 stimulates Syk, PKCδ, and NF-κB, leading to atherosclerosis progression independently of LDL receptor.Nature communications · 2024Article
- Role of PCSK9 inhibitors in the management of dyslipidaemia.Indian heart journal · 2024Review
- First in vivo base-editing trial shows promise.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Genetic and molecular architecture of familial hypercholesterolemia.Journal of internal medicine · 2023Review
- Accuracy and Clinical Impact of Estimating Low-Density Lipoprotein-Cholesterol at High and Low Levels by Different Equations.Biomedicines · 2022Article
- Efficacy and Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors as Adjuvant Treatments for Patients with Hypercholesterolemia Treated with Statin: A Systematic Review and Network Meta-analysis.Frontiers in pharmacology · 2022Article
- Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy.International journal of molecular sciences · 2021Review
- Comparison of Methods to Estimate Low-Density Lipoprotein Cholesterol in Patients With High Triglyceride Levels.JAMA network open · 2021Article
- The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study.Journal of clinical medicine · 2021Article
- PCSK9: A Key Target for the Treatment of Cardiovascular Disease (CVD).Advanced pharmaceutical bulletin · 2020Review
- A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and/or Hypertriglyceridemia.JAMA cardiology · 2020Article
- Integrating DNA sequencing and transcriptomic data for association analyses of low-frequency variants and lipid traits.Human molecular genetics · 2020Article
- Discovery of 2,3'-diindolylmethanes as a novel class of PCSK9 modulators.Bioorganic & medicinal chemistry letters · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
26444323What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.